GCP & Pharmacovigilance Compliance Symposium - D2S02 - Clinical Trials Post-Pandemic
U.S. Food and Drug Administration
Make a clip
Public domain · U.S. Food and Drug Administration
Up to 60 seconds, at most the picture size of the copy it is cut from. The clip carries the title, the credit, the licence and a link back here. It is made in this browser, and nothing is sent to this site.
Or send the moment itself: https://invisiblenetwork.ai/watch/archive/commons/198199294?play=1&t=0
Parts
About
These presentations examined pandemic 'regulatory flexes' and forced changes to clinical trial operations, contrasting them with pre-pandemic activities. This session covered inspection changes during and after the pandemic, including the introduction of Compliance Readiness Inspections (CRIs) with case studies. Innovations in clinical trial assessments during the pandemic were discussed, along with field investigator observations of post-pandemic clinical research impacts. The modern FDA approach to sponsor, clinical investigator, and clinical bioequivalence inspections was outlined to demonstrate regulatory evolution.
Human-made No record of this work says a model made it. What this means.